SCHEMBL22032011

SCHEMBL22032011

CC(=O)N1CC(n2cc(B3OC(C)(C)C(C)(C)O3)cn2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.44
JAK1 P23458 7/20 0.39
TYK2 P29597 7/20 0.39
JAK3 P52333 7/20 0.39
JAK2 O60674 6/20 0.39
KDM4E B2RXH2 1/20 0.34
KDM4A O75164 1/20 0.34
KDM5C P41229 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34
USP30 Q70CQ3 1/20 0.34
MAP4K1 Q92918 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.33
FGFR3 P22607 1/20 0.32
ROCK1 Q13464 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
CHRNB3 Q05901 1/20 0.31
CHRNA6 Q15825 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2363986 0.90 FFAR1 (0.44) FFAR1JAK1TYK2JAK3JAK2
SCHEMBL22086365 0.88 FFAR1 (0.42) FFAR1JAK1TYK2JAK3JAK2
SCHEMBL658691 0.88 FFAR1 (0.42) FFAR1JAK1TYK2JAK3IRAK4
SCHEMBL20899243 0.86 FFAR1 (0.41) FFAR1JAK1TYK2JAK3JAK2
SCHEMBL660078 0.83 USP30 (0.49) FFAR1USP30DGAT1
SCHEMBL23211127 0.83 FFAR1 (0.41) FFAR1JAK1TYK2JAK3KDM5C
SCHEMBL23211118 0.83 FFAR1 (0.41) FFAR1JAK1TYK2JAK3KDM5C
SCHEMBL16342703 0.83 FFAR1 (0.41) FFAR1JAK1TYK2JAK3KDM5C
SCHEMBL21859038 0.83 FFAR1 (0.39) FFAR1USP30IRAK4ROCK1
SCHEMBL21318865 0.82 FFAR1 (0.46) FFAR1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3891158-B1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2025-09-10 EP disclosed
US-20230055250-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-02-23 US disclosed
EP-3891158-A1 MAP4K4 INHIBITORS Imperial College of Science, Technology and Medicine (GB) 2021-10-13 EP disclosed
WO-2020115481-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) 2020-06-11 WO disclosed
WO-2020115481-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055250-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K5, MAP4K1 FFAR1 2666/4885JAK1 1201/4885TYK2 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.